Vimarsana
Biggest News Aggregation in the World

Page 4 - Temre Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Temre Johnson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Temre Johnson Today - Breaking & Trending Today

Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference - Vimarsana News

Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI...

Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference - Vimarsana News

Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 23, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. , a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI HealthCONx Conference,... | November 23, 2021

Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021 - Vimarsana News

Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of...

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer - Vimarsana News

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration...

Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer - Vimarsana News

Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research...